Furthermore, among patients with liver metastases and upfront unresectable left-sided RAS/BRAF WT CRC, the evidence indicates that bevacizumab is equally efficacious as anti-EGFR monoclonal antibodies. Here, BRAF is linked to colorectal carcinoma.